Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

so we invested significantly to expand manufacturing and bring new options to the market, including for those who self-pay for Zepbound® single-dose vials through LillyDirect.” ...

With costly medications or severe drug shortages encouraging the inappropriate reuse of single-dose vials, and a national survey in which 6% of nurses admitted to always or sometimes using this ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

In influenza vaccination, PFSs may cost more per dose than multidose vials (MDVs), but could offer advantages in speed, disposal, wastage and patient safety owing to premeasured accurate doses ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved. Tirzepatide, the active ingredient in the diabetes and ...

Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro ... However, shortages remain for the low-dose version of the weight-loss drug Wegovy, the FDA said. The FDA confirmed ...